Evidence map›Paper›PMID 41840857›Full record

ArticleSynapse (New York, N.Y.)2026

Measurement of Tau Protein and Aβ Amyloid Plaques in Postmortem Human Brains of Down Syndrome and Alzheimer's Disease by Using [

Agnes P Biju, Fariha Karim, Deanna M Schafer, Stephanie A Sison, Christopher Liang, Elizabeth Head, Jogeshwar Mukherjee

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Synapse (New York, N.Y.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Evaluation of [Acta neuropathologica communications · 2026
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors.

Agnes P BijuPreclinical Imaging, Department of Radiological Sciences, University of California-Irvine, Irvine, California, USA.
Fariha KarimPreclinical Imaging, Department of Radiological Sciences, University of California-Irvine, Irvine, California, USA.
Deanna M SchaferPreclinical Imaging, Department of Radiological Sciences, University of California-Irvine, Irvine, California, USA.
Stephanie A SisonPreclinical Imaging, Department of Radiological Sciences, University of California-Irvine, Irvine, California, USA.
Christopher LiangPreclinical Imaging, Department of Radiological Sciences, University of California-Irvine, Irvine, California, USA.
Elizabeth HeadDepartment of Pathology & Laboratory Medicine and Neurology, University of California-Irvine, Irvine, California, USA.
Jogeshwar MukherjeePreclinical Imaging, Department of Radiological Sciences, University of California-Irvine, Irvine, California, USA.

Funding

Novel Tau-Targeted Radiohalogenated Agents for Alzheimer's DiseaseR01AG077700 · UNIVERSITY OF CALIFORNIA-IRVINE · 2025 to 2025
$698k
NIA NIH HHS R01 AG077700NIH HHS AG 077700
6 · The paper itself

Abstract

The accumulation of tau tangles and Aβ plaques are prominent neuropathologies that characterize Alzheimer's disease (AD) and Down syndrome (DS). Continuous developments of PET tracers as biomarkers can be supported by autoradiography to validate effectiveness and accuracy of binding properties that elucidate the pathophysiology of DSAD and AD. This in vitro comparative study evaluates [

Indexed as

Alzheimer DiseaseAmyloid beta-PeptidesBrainDown SyndromePlaque, Amyloidtau ProteinsAgedAged, 80 and overAutoradiographyFemaleHumansIodine RadioisotopesMaleMiddle AgedAmyloid beta-PeptidesIodine Radioisotopestau Proteins[125I]IBETA[125I]IPPIAlzheimer's diseaseamyloid plaquesDown syndrometau

Identifiers

PMID41840857
PMCPMC12993093

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.